ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2013
Evaluation of a polymerase chain reaction-electrospray ionization time-of-flight mass spectrometry for the detection and subtyping of influenza viruses in respiratory specimens.
Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 17 citations in OpenAlex.
- Mass spectrometry analytical responses to the SARS-CoV2 coronavirus in review.Trends in analytical chemistry : TRAC · 2021Review
- Clinical Performance of the AllplexTM Respiratory Panel 1 Test Compared to SimplexaTM Flu A/B and RSV for Detection of Influenza Virus and Respiratory Syncytial Virus Infection Including Their Subtyping.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2019Article
- Public health risks associated with hepatitis E virus (HEV) as a food-borne pathogen.EFSA journal. European Food Safety Authority · 2017Article
- Diagnosing Viral and Atypical Pathogens in the Setting of Community-Acquired Pneumonia.Clinics in chest medicine · 2017Review
- Genotyping Influenza Virus by Next-Generation Deep Sequencing in Clinical Specimens.Annals of laboratory medicine · 2016Article
- Emerging technologies for the clinical microbiology laboratory.Clinical microbiology reviews · 2014Review
- Virological diagnosis of central nervous system infections by use of PCR coupled with mass spectrometry analysis of cerebrospinal fluid samples.Journal of clinical microbiology · 2014Article
- The changing culture of the microbiology laboratory.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2013Article
- A 'culture' shift: Application of molecular techniques for diagnosing polymicrobial infections.Biotechnology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPCR coupled to electrospray ionization mass spectrometry technology (PCR/ESI-TOF-MS) (PLEX-ID system, Abbott Ibis Biosciences) was developed to characterize microbial pathogens.
objectivesTo evaluate the performance of the PLEX-ID flu detection™ kit for detecting Influenza viruses by comparison with the multiplex RespiFinder(®) Kit (PathoFinder). STUDY
designAcute-phase respiratory samples (n=293) were analysed for this purpose. A subpopulation of influenza type A positive samples, identified with the RespiFinder(®) kit (n=64), were subtyped with the RealTime ready Inf A/H1N1 Detection Set(®) (Roche Molecular Diagnostics) and results were compared to the PLEX-ID Flu Detection™ kit.
results274 samples gave concordant results (93.5%, p<0.0001): 65 influenza A-positive, 18 influenza B-positive and 191 negative samples. Of these, 7 samples were PLEX-ID positive/RespiFinder(®) negative (5 influenza A and 2 influenza B) and 12 were PLEX-ID positive/RespiFinder(®) negative (10 influenza A and 2 influenza B). PLEX-ID showed one sample as an influenza A and B co-infection while the RespiFinder(®) assay showed it to be influenza A-positive. The sensitivity, specificity, positive and negative predictive values of the PLEX-ID™ system were 87.4%, 96.5%, 92.2% and 94.1% respectively. Thirteen of 19 discordant samples available for retesting were investigated further with the Anyplex™II RV16 Detection kit (Seegene): seven were RespiFinder(®) concordant, while six were PLEX-ID™ concordant. Subtyping of 61/64 influenza A samples was concordant (95.3%): 55 were H1N1pdm09 and six were non-H1N1pdm09. Three samples gave negative PLEX-ID™ results (one H1N1pdm09 and two non-H1N1pdm09).
conclusionsPCR/ESI-TOF-MS technology showed good diagnostic performances to detect and subtype influenza viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.